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Background: The association between contrast enhanced (CE) and non-contrast
enhanced (NCE) tumor resection and survival in patients with glioblastoma in relation
to molecular subtypes is poorly understood. The aim of this study was to assess the
association between CE and NCE tumor resection and survival in light of MGMT promoter
methylation in newly diagnosed IDH-wildtype glioblastoma.
Materials and methods: Patients with newly diagnosed IDH-wildtype glioblastoma
who underwent surgery were eligible. CE and NCE tumor volumes were assessed
on pre- and post-operative MRI scans and extent of resection was calculated. The
association between CE and NCE tumor resection and survival was evaluated using
multivariable Cox proportional hazards models and Kaplan Meier estimates.
Results: Three hundred and twenty-six patients were included: 177 (54.3%)
with and 149 (45.7%) without MGMT methylation. Multivariable Cox proportional
hazards models stratified for MGMT methylation identified age ≤ 65y (HR 0.63;
95% CI, 0.49–0.81; p < 0.0001), chemoradiation (HR 0.13; 95% CI, 0.09–0.19; p
< 0.0001), maximal CE tumor resection (HR 0.58; 95% CI, 0.39–0.87; p = 0.009),
≥ 30% NCE tumor resection (HR 0.71; 95% CI, 0.53–0.93; p = 0.014), and
minimal residual CE tumor volume (HR 0.64; 95% CI, 0.46–0.88 p = 0.007) as
being associated with longer overall survival. Kaplan Meier estimates showed that
extensive surgery was more beneficial for patients with MGMT methylated glioblastoma.
Incekara et al. Glioblastoma Resection and Survival
Conclusions: This study shows an association between maximal CE tumor resection,
≥30% NCE tumor resection, minimal residual CE tumor volume, and longer overall
survival in patients with newly diagnosed IDH wildtype glioblastoma. Intraoperative
imaging and stimulation mapping may be used to pursue safe and maximal resection. In
future research, the safety aspect of maximizing tumor resection needs to be addressed.
Keywords: glioblastoma, extent of resection, contrast enhanced, non-contrast enhanced, survival, MGMT
INTRODUCTION
Patients with glioblastoma have a poor prognosis with a median
overall survival of 10–15 months, despite safe and maximal
surgical resection followed by chemo- and radiotherapy (1).
This prognosis varies based on known factors such as age, KPS,
extent of resection, isocitrate dehydrogenase (IDH) mutation
status, and methylguanine methyltransferase (MGMT) promoter
methylation status (2, 3).
Maximal resection of the contrast enhanced (CE) portion
of glioblastoma has been associated with better overall survival
and is currently part of standard surgical glioblastoma treatment
(3). However, glioblastoma is known to infiltrate far beyond the
margins of CE as seen onMRI, into the surrounding non-contrast
enhanced (NCE) edematous T2-weighted or FLAIR abnormality
area (4). This raises the question whether maximal CE tumor
resection should be extended beyond CE, into NCE area, to
improve survival (5). A recent meta-analysis and a systematic
review suggested that there is an association betweenmaximal CE
tumor resection with resection of NCE tumor and overall survival
(5, 6). However, the quality of evidence of the available studies
was low due to confounding and selection biases. On top, studies
investigating the impact of CE and NCE resection have reported
limited molecular data on IDH mutation and MGMT promoter
methylation of their studied glioblastoma population (6, 7).
Thus, in light of the WHO 2016 reclassification, which
now includes such molecular data, the association between
CE and NCE glioblastoma resection and survival needs to
be re-evaluated in a molecularly homogenous glioblastoma
IDH-wildtype population, while considering MGMT promoter
methylation (8). The aim of this study therefore, was to assess the
association between CE and NCE tumor resection and survival
in light of MGMT promoter methylation in a cohort of patients
with newly diagnosed IDH-wildtype glioblastoma.
MATERIALS AND METHODS
Patients
All consecutive patients aged 18 years or older, newly
diagnosed with a CE mass lesion as seen on post-contrast
T1-weighted MRI scans, histopathological confirmed as IDH-
wildtype glioblastoma, who underwent tumor resection or biopsy
between January 2012 and May 2018 at Erasmus Medical Center
Abbreviations: CE, contrast enhancement; IDH, isocitrate dehydrogenase;
MGMT, O6-Methylguanine-DNA Methyltransferase; NCE, non-contrast
enhancement.
Rotterdam were considered for this retrospective study. Patients
were eligible if pre- and immediate post-operative (<48 h) T2-
weighted or FLAIR and post-contrast T1-weighted MRI scans
were available together with complete molecular data on IDH
mutation and MGMT methylation. Molecular analysis was post-
hoc performed in patients with unknown IDH mutation or
MGMT methylation status; patients without enough tumor
material for molecular analysis or in whom assays failed to
produce a test result were excluded. The study was approved
by the Medical Ethical Committee of Erasmus Medical Center
Rotterdam, who waived the need for written informed consent
from the patients due to the retrospective nature of this study
and the (emotional) burden that would result from contacting
the patients or their relatives to obtain consent. The study was
performed in accordance with the 1964 Helsinki Declaration
and its later amendments or comparable ethical standards
and reported following the Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) guidelines.
Image Acquisition, Tumor Segmentation,
and Extent of Resection
From pre- and post-operative MRI scans, which were obtained in
the clinical routine either on a 1.5T or 3.0T scanner, post-contrast
T1-weighted and T2-weighted or FLAIR images were collected.
For glioblastoma segmentation, we imported both pre- and
post-operative post-contrast T1-weighted and T2-weighted or
FLAIR scans into Brainlab (BrainLab, Feldkirchen, Germany,
version 2.1.0.15). Using the SmartBrush tool in Brainlab
Elements, we semi-automatically segmented all tumor involved
CE on pre-operative post-contrast T1-weighted scans (including
the necrotic part, if present) and all tumor involved CE on
post-operative post-contrast T1-weighted scans (excluding small
vessels in the surgical cavity or hemorrhage). We then semi-
automatically segmented all tumor-related NCE on both pre-and
post-operative T2-weighted or FLAIR scans (excluding extra-
lesional hemorrhage). We attempted to minimize the inclusion
of surgery induced new T2-weighted or FLAIR abnormality
by overlaying and carefully comparing pre- and post-operative
MRIs. We manually corrected all segmentations when needed
using the manual Brush tool. All tumor volumes were assessed
while being blinded for patients’ clinical outcome.
We finally obtained four tumor volumes (cm3): pre-operative
and residual CE volumes and pre-operative and residual NCE
volumes. We calculated the CE surrounding NCE volumes
by subtracting CE volumes from the total NCE volumes. We
calculated the extent of resection (EOR,%) separately for both the
CE and NCE portion with the formula: [(pre-operative volume
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– residual volume)/pre-operative volume] ∗ 100 (9). Maximal
CE resection was categorized in our dataset as CE EOR >97%.
NCE tumor resection was dichotomized into ≥30% resection
and<30% resection based on threshold analyses (Figures S1, S2)
and analyzed independently from CE tumor resection (i.e.,
irrespective of whether complete CE tumor resection was
achieved or not). Tumors that were biopsied were segmented
only on pre-operative MRI scans and their EOR was imputed as
being 0%. In addition to the CE EOR categories (biopsy, subtotal,
maximal resection), we categorized CE residual tumor volumes
in >5, 1–5, and 0–1 cm3. While CE EOR is in part defined by CE
residual tumor volume (as given by the above-mentioned EOR
formula), the categories are not identical due to variations in
pre-operative tumor volume.
Molecular Analysis
Tumor tissue samples were obtained from patients through
surgical resection or biopsy. Histopathological examination was
performed by neuropathologists; IDH mutational analysis was
assessed with Sanger sequencing or targeted next generation
sequencing and MGMT methylation status was assessed with a
methylation specific PCR, as described elsewhere (10–12).
Statistical Analysis
Overall survival was defined as time from surgery to death
(primary outcome) and progression-free survival (PFS) was
defined as time from surgery till clinical or radiological
progression (secondary outcome). Patients were censored at time
of last clinical follow up date.
Statistical analyses were performed with SPSS 25.0 statistical
software (IBM Corp.). Pre-operative and post-operative residual
tumor volume distributions were skewed and therefore log
transformed prior to statistical analysis. Descriptive statistics
were tested between MGMT methylation status groups with the
Chi Squared Test or Fisher Exact test in case of categorical
variables, with the Kruskal Wallis test in case of continuous
non-normal distributed data and with log rank tests to
compare median overall survival and PFS when using Kaplan
Meier analysis.
The associations between each variable and outcome were
first tested with univariable Cox proportional hazards models
and all variables with p < 0.10 (entry significance threshold)
were selected for multivariable Cox proportional hazards models.
These models were stratified for MGMT, because this variable
violated the proportional hazards assumption. Hazard ratio
(HR) with 95% Confidence interval (CI) was estimated for
each variable within the model. A p < 0.05 was considered
statistically significant.
RESULTS
There were 375 glioblastoma patients considered for this study.
We excluded 36 (9.6%) due to insufficient tissue material for
molecular analysis, and 13 (3.5%) because of the presence of
IDH mutation. In total, 326 IDH-wildtype glioblastoma were
included in our analysis: 177 (54.3%) with and 149 (45.7%)
without MGMT promoter methylation. Maximal CE resection
was achieved in 61 patients (18.7%), while in 187 (57.4%) patients
maximal resection of CE could not be achieved. Seventy-eight
patients (23.9%) underwent biopsy. In 156 (47.9%) patients,
≥30% NCE tumor resection was achieved and in 170 (52.1%)
patients 0–30% NCE tumor resection was achieved. Median
overall survival and PFS was 309 days (95% CI, 278–340) and 174
days (95% CI, 159–209), respectively. Further patient and tumor
characteristics are presented in Table 1.
Univariable Cox proportional hazards regression analysis
identified age ≤ 65y (HR 0.64; 95% CI, 0.51–0.80; p < 0.0001),
KPS >70 (HR 0.59; 95% CI, 0.47–0.74; p < 0.0001), MGMT
promoter methylation (HR 0.72; 95% CI, 0.57–0.90; p < 0.004),
adjuvant chemoradiation (HR 0.14; 95% CI, 0.11–0.19; p <
0.0001), smaller pre-operative CE tumor volumes (per cm3
HR 0.92; 95% CI, 0.83–1.01; p < 0.094), maximal CE tumor
resection (HR 0.51; 95% CI, 0.36–0.72; p < 0.0001), and ≥30%
NCE tumor resection (HR 0.72; 95% CI, 0.58–0.91; p = 0.005)
as being associated with longer overall survival. As further
presented in Table 2, the variables age≤ 65y, KPS > 70, adjuvant
chemoradiation, maximal CE resection, and ≥30% NCE tumor
resection were also significantly associated with a longer PFS in
univariable Cox regression analysis (p < 0.05). Kaplan Meier
curves for overall survival and PFS for each variable are presented
in Figure S3.
Multivariable Cox proportional hazards regression analysis
stratified for MGMTmethylation status and risk adjusted for age
≤ 65y (HR 0.63; 95% CI, 0.49–0.81; p < 0.0001), KPS > 70 (HR
0.92; 95% CI, 0.71–1.19; p = 0.545), adjuvant chemoradiation
(HR 0.13; 95% CI, 0.09–0.19; p < 0.0001), and smaller pre-
operative CE tumor volumes per cm3 (HR 0.85; 95% CI, 0.75–
0.95; p = 0.007) identified maximal CE tumor resection (HR
0.58; 95% CI, 0.39–0.87; p = 0.009) and ≥30% NCE tumor
resection (HR 0.71; 95% CI, 0.53–0.93; p = 0.014) as being
associated with longer overall survival (Table 2). Variables that
remained significantly associated with a longer PFS were KPS
> 70 (HR 0.59; 95% CI, 0.45–0.77; p < 0.0001) and adjuvant
chemoradiation (HR 0.09; 95% CI, 0.06–0.14; p < 0.0001).
Explorative multivariable Cox proportional hazards regression
analyses showed that higher NCE tumor resection thresholds
(e.g., ≥50%) were not associated with a favorable overall survival
(p > 0.05) (for threshold analysis, see Figure S1).
Kaplan Meier estimates suggested that the impact of maximal
CE tumor resection was more beneficial for patients with MGMT
methylated glioblastoma and that it significantly improved
median overall survival (572 days; 95% CI, 424–720), when
compared to STR (342 days; 95% CI, 282–402; p = 0.014) or
biopsy (112 days; 95%CI, 36–42; p= 0.001) (Figure 1A). Patients
with MGMT methylated glioblastoma also had a longer overall
survival with ≥30% NCE tumor resection (425 days; 95% CI,
286–564) than with <30% NCE tumor resection (190 days; 95%
CI, 107–273; p = 0.001) (Figure 1B). In patients with MGMT
unmethylated glioblastoma, no survival benefit was observed
with ≥30% NCE resection (p= 0.884).
We further assessed minimal post-operative CE residual
volumes with a potential positive impact on overall survival. In
MGMT methylated glioblastoma, when compared to >5 cm3
residual CE tumor (224 days; 95% CI 164–284), we observed
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TABLE 1 | Patient and tumor characteristics.
Characteristics MGMT promoter
All n % Methylated n % Unmethylated n % p-value
326 100 177 54.3 149 45.7
Sex 0.006
Male 206 63.2 100 48.5 106 51.5
Female 120 36.8 77 64.2 43 35.8
Age, Years 0.122
≤65 162 49.7 81 50.0 81 50.0
>65 164 50.3 96 58.5 68 41.5
Mean, years (SD) 63.8 (10.5) 64.2 (10.9) 63.3 (10.1) 0.453
KPS 0.748
≤ 70 119 36.5 66 55.5 53 45.5
> 70 207 73.5 111 53.6 96 46.4
Mean (SD) 79.2 (12.4) 78.8 (12.2) 79.7 (12.6) 0.480
Pre-operative Tumor Volume, Median cm3 (IQR)
CE 34.9 (15.5–55.8) 30.7 (13.8–52.5) 39.9 (17.1–26.2) 0.050
NCE 72.1 (29.4–127.5) 78.1 (27.8–133.8) 64.9 (32.3–113.4) 0.249
Residual Tumor Volume, Median cm3 (IQR)
CE 5.0 (1.41–12.3) 6.1 (1.8–12.5) 3.8 (1.1–12.0) 0.097
NCE 39.7 (18.3–73.7) 42.2 (17.1–79.6) 36.5 (20.4–64.2) 0.699
Maximal CE Resection 0.213
Yes 61 18.7 27 44.3 34 55.7
No 187 57.4 105 56.2 82 43.8
Biopsy 78 23.9 45 57.7 33 42.3
Median EOR (IQR) 83.4 (14.2-94.8) 79.6 (0-91.9) 88.0 (25-7-96.0) 0.075
NCE Resection 0.609
≥30% 156 47.9 87 55.8 69 44.2
<30% 170 52.1 90 52.9 80 47.1
Median EOR (IQR) 27.1 (0–57.1) 28.7 (0–58.4) 25.8 (0–55.0) 0.948
Adjuvant Therapy 0.294
No therapy 61 18.7 38 62.3 23 37.7
Radio- or chemotherapy alone 56 17.2 27 48.2 29 51.8
Chemoradiation 209 64.1 112 58.4 97 41.6
Overall Patient Outcome
Median overall survival (95% CI) 309 (278.0–340.0) 334 (266.8–401.2) 305 (275.2-334.8) 0.003
Median progression-free survival (95% CI) 184 (159.3–208.7) 174 (131.2–216.8) 190 (162.0–218) 0.053
MGMT, methylguanine methyltransferase; SD, standard deviation; CE, contrast enhancement; NCE, non contrast enhancement; EOR, extent of resection; IQR, Inter Quartile Range; CI,
Confidence interval.
a significantly longer median overall survival for a residual CE
tumor volume of 1–5 cm3 (470 days; 95% CI 330–610; p <
0.0001) and 0–1 cm3 (536 days; 95% CI 319–752; p = 0.003)
(Figure 1C). In MGMT unmethylated glioblastoma, we only
observed a longer overall survival in residual CE volumes of
0–1 cm3 (427 days; 95% CI, 350–503), when compared to 1–
5cm3 (299 days; 95% CI, 270–327; p = 0.006) or to >5 cm3
(200 days; 95% CI, 102–298; p = 0.003) (Figure 1C). In these
tumors, no difference in median overall survival was observed
between 1–5 and >5 cm3 (p = 0.371) residual CE tumor
volume. Multivariable Cox proportional hazards regression
analysis stratified for MGMT and adjusted for age, KPS, adjuvant
chemoradiation, and pre-operative CE tumor volume, identified
a residual CE tumor volume of 0–1 cm3 (HR 0.64; 95% CI,
0.46–0.88 p= 0.007), and 1–5 cm3 (HR 0.71; 95%CI, 0.54–0.94; p
= 0.016) as being associated with favorable overall survival. These
analyses were also performed for post-operative residual NCE
volumes, but here no minimal volume threshold with a positive
impact on overall survival was identified.
DISCUSSION
This study shows an association between maximal CE tumor
resection, ≥30% NCE tumor resection, minimal residual CE
tumor volume and longer overall survival in 326 patients




































Univariable Multivariable Univariable Multivariable
HR, 95% CI P-Value# Adjusted HR,
95% CI




>65 259, 191–327 a 144, 114–175 a
≤65 358, 311–405 0.64, 0.51–0.80 <0.0001 0.63, 0.49–0.81 <0.0001 216, 181–251 0.70, 0.56–0.89 0.003 0.82, 0.64–1.06 0.123
KPS
≤70 199, 142–256 a 120, 91–149 a
>70 369, 319–419 0.59, 0.47–0.74 <0.0001 0.92, 0.71–1.19 0.545 223, 181–265 0.51, 0.40–0.65 <0.0001 0.59, 0.45–0.77 <0.0001
MGMT Promoter
Unmethylated 305, 275–335 a b 190, 162–218 a b
Methylated 334, 267–401 0.72, 0.57–0.90 0.004 174, 131–217 0.79, 0.62–1.00 0.054
Adjuvant Therapy
None 65, 46–84 a 47, 38–56 a
Radiotherapy or chemotherapy 217, 146–288 0.38, 0.26–0.55 <0.0001 0.29, 0.19–0.43 <0.0001 129, 107–151 0.23, 0.15–0.36 <0.0001 0.22, 0.14–0.35 <0.0001
Chemoradiation 423, 367–479 0.14, 0.11–0.19 <0.0001 0.13, 0.09–0.19 <0.0001 254, 222–287 0.09, 0.06–0.13 <0.0001 0.09, 0.06–0.14 <0.0001
Pre-operative CE Tumor Volume
smaller per cm3 0.92, 0.83–1.01 0.094 0.85, 0.75–0.95 0.007 0.94, 0.85–1.04 0.239 0.99, 0.88–1.11 0.860
Maximal CE Resection * *
Biopsy 153, 106–200 a 100, 87–113 a
No 309, 278–340 0.79, 0.60–1.04 0.090 0.87, 0.61–1.23 0.415 190, 170–210 0.80, 0.61–1.05 0.109 1.25, 0.89–1.81 0.228
Yes 441, 321–560 0.51, 0.36–0.72 <0.0001 0.58, 0.39–0.87 0.009 272, 210–334 0.59, 0.42–0.85 0.004 0.97, 0.63–1.50 0.898
NCE Resection * *
<30% 266, 213–319 a 155, 104–206 a
≥30% 344, 304–385 0.72, 0.58–0.91 0.005 0.71, 0.53–0.93 0.014 203, 166–240 0.82, 0.65–1.03 0.087 0.87, 0.65–1.15 0.325
aReference group.
bProportional hazard assumption for MGMT was violated, therefore multivariable Cox regression model was stratified for MGMT.
HR, Hazard ratio; MGMT, methylguanine methyltransferase, CI Confidence Interval.
*for MGMT-stratified median overall survival, see Figure 1.
#entry significance threshold of p < 0.1.
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FIGURE 1 | Overall and MGMT-stratified Kaplan Meier curves for overall survival (A) Maximal CE resection (B) NCE resection and (C) CE residual volume.
with newly diagnosed IDH-wildtype glioblastoma. We observed
that extensive resection was more beneficial for patients
with MGMT methylated IDH-wildtype glioblastoma in terms
of survival.
Maximal resection of CE has earlier been associated with
longer overall survival in a large meta-analysis of neurosurgical
literature based on 37 studies and 41,117 unique glioblastoma
patients (3). This association has recently been re-evaluated
based on two new insights. First, studies performed before
the WHO 2016 reclassification have included limited molecular
data, because the impact of molecular subtyping of glioblastoma
according to IDH mutation status was less of a consideration
(3, 7, 13–15). Although IDH mutation within newly diagnosed
primary glioblastoma is rare (<5 and 3.5% in our cohort)
these tumors represent a distinct molecular type of glioma
arising from a distinct precursor lesion (16, 17). Therefore,
incomplete or absence of molecular data on IDH mutation
and MGMT methylation or mixing molecular subtypes when
evaluating the impact of glioblastoma resection on survival
is undesirable. More recent studies did investigate the impact
of glioblastoma surgery on survival in light of molecular
markers. A recent study investigated the impact of maximal
CE resection and MGMT promoter methylation status in a
homogenous IDH-wildtype glioblastoma population (n = 175)
and showed that both were significantly associated with
longer overall survival (2). Ellingson et al. showed in 1,054
glioblastoma patients (with partially available data on IDH
mutation and MGMT methylation) that smaller residual CE
tumor volumes (<12 cm3) and MGMT methylation were
significantly associated with longer overall survival in patients
receiving chemoradiation (18). A recent study published by
Molinaro et al. confirmed the association between maximal CE
resection and overall survival across all molecular subgroups of
glioblastoma (19).
Secondly, the association between glioblastoma resection and
overall survival is also being reassessed by evaluating the value
of NCE tumor resection, because it is known that glioblastoma
infiltrates beyond the margins of CE into the NCE area (4). This
aspect of glioblastoma surgery is also recently investigated by
Molinaro et al. (19). The authors found that maximal resection
of CE and NCE tumor was associated with longer overall
survival in younger patients with IDH wildtype glioblastoma
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regardless of MGMT methylation status (subset of 190 patients
with known IDH mutation and MGMT methylation status). In
their study, maximal NCE resection that was associated with
overall survival was defined as 92% NCE tumor resection after
maximal CE tumor resection. Other studies have associated
lower NCE tumor resection thresholds of 53% and 45% with
overall survival (7, 20). We observed that a NCE tumor resection
threshold of 30% was associated with overall survival. This
association was studied CE tumor resection (i.e., irrespective of
whether patients did or did not undergo complete CE tumor
resection). In exploratory threshold analysis, higher thresholds
(e.g., minimal ≥60% NCE tumor resection) seemed not to be
associated with overall survival anymore. This may suggest that
resection of NCE tumor immediately surrounding CE improves
survival, but extending the resection on further distance from
CE into NCE tumor does not provide survival benefit. It
can be hypothesized that the direct peritumoral NCE area
reflects a higher degree of tumor infiltration than the NCE
area further away from the CE tumor, which is presumably
more dominated by edema than tumor infiltration (4). In future
research, a combination of physiological imaging modalities
(such as MR spectroscopy, diffusion and perfusion imaging or
positron-emission tomography) may be used to more accurately
detect tumor infiltrated portions in NCE and to tailor surgical
planning (21).
Importantly, maximal tumor resection should not be
attempted at all cost. Previous studies assessing the value of
extensive tumor resection generally reported no or only limited
data on eloquent tumor location, neurological outcome or
quality of patient life (3, 22, 23). The safety of extensive tumor
resection is thus mostly unknown and should only be attempted
with intraoperative imaging guidance and/or awake surgery
with stimulation mapping, especially when tumors are closely
related to eloquent brain area (24). While frontal or temporal
pole tumor can commonly be removed more safely, posterior
frontal or parietal tumors should be approached with more
caution (25, 26).
In line with this, one limitation of this retrospective study is
that we did not have sufficient data on eloquent tumor location
or neurological outcome of patient after surgery. Therefore,
the safety of extensive resection needs further investigation
before clinical recommendations and the translation of potential
survival benefits, into real world clinical practice can be
made. Another limitation of this study is its retrospective
nature. This may have introduced some degree of selection
bias. We attempted to limit selection bias by consecutive
inclusion of all glioblastoma patients operated upon between
2012 and 2018 in our cohort, including patients with complex
glioblastoma localization (crossing midline or deep within the
basal ganglia) who underwent diagnostic biopsies. We also
performed IDH mutational and MGMT promoter methylation
analyses on all glioblastoma included in our cohort. A third
limitation is that only one observer assessed both pre- and
post-operative tumor volumes. In this context, a stringent
assessment of residual volumes in the resection cavity by
one observer may explain the relatively low maximal CE
resection percentage of 17.8%. Although the interobserver
agreement is high for pre-operative volumes, it is known
to be relatively low for residual tumor volumes. The intra-
observer agreement nevertheless, is known to be high for
both pre-operative as residual tumor volumes (9, 12). We
have also attempted to limit bias during volumetric assessment
by blinding the assessor for patients’ clinical outcome. In
future research, our findings need to be validated in an
external validation. Ideally, the safety of maximizing tumor
resection beyond CE tumor margins should be assessed in
well-designed well-powered trials with safety measures as
primary endpoint.
To conclude, this study shows an association between
maximal CE tumor resection, ≥30% NCE tumor resection,
minimal residual CE tumor volume, and longer overall survival
in patients with newly diagnosed IDH wildtype glioblastoma.
Extensive resection was more beneficial for patients with MGMT
methylated glioblastoma. Intraoperative imaging and stimulation
mapping may be used to pursue maximal tumor resection during
glioblastoma surgery. In future research, the safety aspect of
maximizing tumor resection needs to be addressed.
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